Dynamic contrast-enhanced MRI in oncology drug development

Current Clinical Pharmacology

Volumn 2, Issue 2, 2007, Pages 111-122

  Cheng, Hai Ling Margaret ^a,b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; Antiangiogenic cancer therapy; Drug development; Dynamic contrast enhanced magnetic resonance imaging (DCE MRI); Imaging molecular biomarkers; Oncology

Indexed keywords

ALPHAVBETA5 INTEGRIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOCHEMICAL MARKER; CD36 ANTIGEN; CELECOXIB; CILENGITIDE; COMBRETASTATIN A4; CONTRAST MEDIUM; DALTEPARIN; ENDOGLIN; GADOLINIUM PENTETATE; INDOCYANINE GREEN; IODINATED CONTRAST MEDIUM; SUNITINIB; TAMOXIFEN CITRATE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VATALANIB; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR;

BLOOD VOLUME; CALCULATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CAPILLARY PERMEABILITY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORRELATIONAL STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG SYNTHESIS; DRUG TARGETING; ECHOGRAPHY; HEMODYNAMIC PARAMETERS; HEMODYNAMICS; HUMAN; IMAGING SYSTEM; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MICROVASCULATURE; NEAR INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; SENSITIVITY ANALYSIS; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; REGIONAL BLOOD FLOW;

EID: 34249338085     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488407780598180     Document Type: Review

References (94)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29(6 Suppl, 16): 15-8.
2. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 1995; 6: 3-18.
3. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 2000; 5(Suppl 1): 20-7.
4. Westphal JR, Van't Hullenaar R, Peek R, et al. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer 2000; 86: 768-76.
5. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
6. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-9.
7. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2001; 2: 278-89.
8. Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 2004; 4(Suppl 2): S62-8.
9. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006; 24: 3293-8.
10. Dewhirst MW. Angiogenesis and blood flow in solid tumors. In: Teicher BA, Ed. Drug resistance in oncology. New York: Dekker; 1993; 3-24.
11. Braun RD, Lanzen JL, Dewhirst MW. Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats. Am J Physiol 1999; 277(2 Pt 2): H551-68.
12. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002; 2: 266-76.
13. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999; 237: 97-132.
14. Stomper PC, Winston JS, Herman S, Klippenstein DL, Arredondo MA, Blumenson LE. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res Treat 1997; 45: 39-46.
15. Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999; 10: 260-6.
16. Thorpe PE, Chaplin DJ, Blakey DC. The first international conference on vascular targeting: meeting overview. Cancer Res 2003; 63: 1144-7.
17. Preda A, Novikov V, Moglich K et al. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging 2004; 20: 865-73.
18. Drevs J, Muller-Driver R, Wittig C, et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002; 62: 4015-22.
19. Li WW. Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad Radiol 2000; 7: 800-11.
20. Miles KA, Charnsangavej C, Lee FT, Fishman EK, Horton K, Lee TY. Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 2000; 7: 840-50.
21. Bacharach SL, Libutti SK, Carrasquillo JA. Measuring tumor blood flow with H(2)(15)O: practical considerations. Nucl Med Biol 2000; 27: 671-6.
22. Ferrara KW, Merritt CR, Burns PN, Foster FS, Mattrey RF, Wickline SA. Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. Acad Radiol 2000; 7: 824-39.
23. Neeman M, Provenzale JM, Dewhirst MW. Magnetic resonance imaging applications in the evaluation of tumor angiogenesis. Semin Radiat Oncol 2001; 11: 70-82.
24. Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 2001; 56: 607-20.
25. Bhujwalla ZM, Artemov D, Glockner J. Tumor angiogenesis, vascularization, and contrast-enhanced magnetic resonance imaging. Top Magn Reson Imaging 1999; 10: 92-103.
26. Barbier EL, Lamalle L, Decorps M. Methodology of brain perfusion imaging. J Magn Reson Imaging 2001; 13: 496-520.
27. Simonsen CZ, Ostergaard L, Smith DF, Vestergaard-Poulsen P, Gyldensted C. Comparison of gradient- and spin-echo imaging: CBF, CBV, and MTT measurements by bolus tracking. J Magn Reson Imaging 2000; 12: 411-6.
28. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med 1996; 36: 715-25.
29. Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 2005; 30: 324-41.
30. Cheng HL, Wright GA. Rapid high-resolution T(1) mapping by variable flip angles: accurate and precise measurements in the presence of radiofrequency field inhomogeneity. Magn Reson Med 2006; 55: 566-74.
31. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999; 10: 254-9.
32. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997; 7: 91-101.
33. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
34. St Lawrence KS, Lee TY. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: I. Theoretical derivation. J Cereb Blood Flow Metab 1998; 18: 1365-77.
35. Leach MO, Brindle KM, Evelhoch JL, et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol 2003; 76(Spec No 1): S87-91.
36. Brasch R, Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol 2000; 34: 148-55.
37. Detre JA, Zhang W, Roberts DA, et al. Tissue specific perfusion imaging using arterial spin labeling. NMR Biomed 1994; 7: 75-82.
38. Roberts TP, Turetschek K, Preda A, et al. Tumor microvascular changes to anti-angiogenic treatment assessed by MR contrast media of different molecular weights. Acad Radiol 2002; 9(Suppl 2): S511-3.
39. Galbraith SM, Lodge MA, Taylor NJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002; 15: 132-42.
40. Jackson A, Jayson GC, Li KL, et al. Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol 2003; 76: 153-62.
41. Henderson E, Rutt BK, Lee TY. Temporal sampling requirements for the tracer kinetics modeling of breast disease. Magn Reson Imaging 1998; 16: 1057-73.
42. Look DC, Locker DR. Time saving in measurement of NMR and EPR relaxation times. Rev Sci Instrum 1970; 41: 250-1.
43. Deoni SC, Rutt BK, Peters TM. Rapid combined TI and T2 mapping using gradient recalled acquisition in the steady state. Magn Reson Med 2003; 49: 515-26.
44. Fritz-Hansen T, Rostrup E, Larsson HB, Søndergaard L, Ring P, Henriksen O. Measurement of the arterial concentration of Gd-DTPA using MRI: a step toward quantitative perfusion imaging. Magn Reson Med 1996; 36: 225-31.
45. van Osch MJ, Vonken EJ, Viergever MA, van der Grond J, Bakker CJ. Measuring the arterial input function with gradient echo sequences. Magn Reson Med 2003; 49: 1067-76.
46. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991; 17: 357-67.
47. Parker GJ, Roberts C, Macdonald A, et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 2006; 56: 993-1000.
48. Akbudak E, Conturo TE. Arterial input functions from MR phase imaging. Magn Reson Med 1996; 36: 809-15.
49. Cheng HL. T(1) measurement of flowing blood and arterial input function determination for quantitative 3D T1-weighted DCE-MRI. In: Proceedings of the 14th Scientific Meeting of the International Society of Magnetic Resonance in Medicine; 2006 May 6-12; Seattle, USA. (abstract 385)
50. Buonaccorsi GA, Roberts C, Choung S, et al. Comparison of the performance of tracer kinetic model-driven registration for dynamic contrast enhanced MRI using different models of contrast enhancement Acad Radiol 2006; 13: 1112-23.
51. Taylor NJ, Lankester KJ, Stirling JJ, et al. Application of navigator techniques to breath-hold DCE-MRI studies of the liver. In: Proceedings of the 11th Scientific Meeting of the International Society of Magnetic Resonance in Medicine; 2003 Jul 10-16; Toronto, Canada. (abstract 1306)
52. Donahue KM, Weisskoff RM, Chesler DA, et al. Improving MR quantification of regional blood volume with intravascular T1 contrast agents: accuracy, precision, and water exchange. Magn Reson Med 1996; 36: 858-67.
53. Chan AA, Nelson SJ. Simplified gamma-variate fitting of perfusion curves. EEEE Biomed Imag Proc 2004; 2: 1067-70.
54. Daldrup-Link HE, Kaiser A, Helbich T, et al. Macromolecular contrast medium (feruglose) versus small molecular contrast medium (gadopentetate) enhanced magnetic resonance imaging: differentiation of benign and malignant breast lesions. Acad Radiol 2003; 10: 1237-46.
55. Barentsz JO, Jager GJ, van Vierzen PB, et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. Radiology 1996; 201: 185-93.
56. Mayr NA, Yuh WT, Magnotta VA, et al. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int J Radiat Oncol Biol Phys 1996; 36: 623-33.
57. Blomqvist L, Fransson P, Hindmarsh T. The pelvis after surgery and radio-chemotherapy for rectal cancer studied with Gd-DTPA-enhanced fast dynamic MR imaging. Eur Radiol 1998; 8: 781-7.
58. Hoskin PJ, Saunders MI, Goodchild K, Powell ME, Taylor NJ, Baddeley H. Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol 1999; 72: 1093-8.
59. Barentsz: JO, Berger-Hartog O, Witjes JA, et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 1998; 207: 791-7.
60. Hawighorst H, Knapstein PG, Knopp MV, Vaupel P, van Kaick G. Cervical carcinoma: standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. MAGMA 1999; 8: 55-62.
61. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tamour stage, histological grade and PSA. Clin Radiol 2000; 55: 99-109.
62. Nagashima T, Suzuki M, Yagata H, et al. Dynamic-enhanced MRI predicts metastatic potential of invasive ductal breast cancer. Breast Cancer 2002; 9: 226-30.
63. Buckley DL, Drew PJ, Mussurakis S, Monson JR, Horsman A. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging 1997; 7: 461-4.
64. Buadu LD, Murakami J, Murayama S, et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 1996; 200: 639-49.
65. Hulka CA, Edmister WB, Smith BL, et al. Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 1997; 205: 837-42.
66. Hawighorst H, Weikel W, Knapstein PG, et al. Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 1998; 4: 2305-12.
67. Tynninen O, Aronen HJ, Ruhala M, et al. MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Invest Radiol 1999; 34: 427-34.
68. Su MY, Cheung YC, Fruehauf JP, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 2003; 18: 467-77.
69. Hoang BH, Dyke JP, Koutcher JA, et al. VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI. Clin Orthop Relat Res 2004; (426): 32-8.
70. Matsubayashi R, Matsuo Y, Edakuni G, Satoh T, Tokunaga O, Kudo S. Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology 2000; 217: 841-8.
71. Bhujwalla ZM, Axtemov D, Natarajan K, Ackerstaff E, Solaiyappan M. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 2001; 3: 143-53.
72. Gossmann A, Helbich TH, Kuriyamua N, et al. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 2002; 15: 233-40.
73. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955-64.
74. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34.
75. Wedam. SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24: 769-77.
76. O'Donnell A, Padhani A, Hayes C, et al. A Phase I study of the angiogenesis inhibitor SU5416 (semaxamb) in solid turnours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer 2005; 93: 876-83.
77. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002; 94: 1484-93.
78. Galbraith SK Rustin GJ, Lodge MA, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002; 20: 3826-40.
79. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005; 23: 5464-73.
80. Mross K, Drevs J, Muller M, et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005; 41: 1291-9.
81. Pham CD, Roberts TP, van Bruggen N, et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998; 16: 225-30.
82. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003; 21: 2831-42.
83. Padhani AR, Hayes C, Landau S, Leach MO. Reproducibility of quantitative dynamic MRI of normal human tissues. NMR Biomed 2002; 15: 143-53.
84. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 2000; 156: 1345-62.
85. Brekken RA, Huang X, King SW, Thorpe PE. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998; 58: 1952-9.
86. Bredow S, Lewin K Hofmann B, Marecos E, Weissleder R. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer 2000; 36: 675-81.
87. Bogdanov A Jr, Marecos E, Cheng HC, et al. Treatment of experimental brain tumors with trombospondin-1 derived peptides: an in vivo imaging study. Neoplasia 1999; 1: 438-45.
88. Lee WS, Jain MK, Arkonac BM, et al. Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines. Circ Res 1998; 82: 845-51.
89. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000; 289: 1197-202.
90. Li KC, Guccione S, Bednarski MD. Combined vascular targeted imaging and therapy: a paradigm for personalized treatment. J Cell Biochem Suppl 2002; 39: 65-71.
91. Winter PM, Caruthers SD, Kassner A, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003; 63: 5838-43.
92. Winter PM, Morawski AM, Caruthers SD, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003; 108: 2270-4.
93. Montet Y, Montet-Abou K, Reynolds F, Weissleder R, Josephson L. Nanoparticle imaging of integrins on tumor cells. Neoplasia 2006; 8: 214-22.
94. Winter PM, Neubauer AM, Caruthers SD, et al. Endothelial alpha(v)beta3-integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 2103-9.